- Home
- LSF vs CNTX Comparison
LSF vs CNTX Comparison
Compare LSF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- CNTX
- Stock Information
- Founded
- LSF 2015
- CNTX 2015
- Country
- LSF United States
- CNTX United States
- Employees
- LSF N/A
- CNTX N/A
- Industry
- LSF Packaged Foods
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- CNTX Health Care
- Exchange
- LSF Nasdaq
- CNTX Nasdaq
- Market Cap
- LSF 71.7M
- CNTX 67.7M
- IPO Year
- LSF 2020
- CNTX 2021
- Fundamental
- Price
- LSF $7.27
- CNTX $0.81
- Analyst Decision
- LSF Strong Buy
- CNTX Strong Buy
- Analyst Count
- LSF 2
- CNTX 5
- Target Price
- LSF $7.75
- CNTX $6.70
- AVG Volume (30 Days)
- LSF 59.9K
- CNTX 151.3K
- Earning Date
- LSF 02-26-2025
- CNTX 03-20-2025
- Dividend Yield
- LSF N/A
- CNTX N/A
- EPS Growth
- LSF N/A
- CNTX N/A
- EPS
- LSF N/A
- CNTX N/A
- Revenue
- LSF $40,896,326.00
- CNTX N/A
- Revenue This Year
- LSF $27.95
- CNTX N/A
- Revenue Next Year
- LSF $21.07
- CNTX N/A
- P/E Ratio
- LSF N/A
- CNTX N/A
- Revenue Growth
- LSF 20.33
- CNTX N/A
- 52 Week Low
- LSF $0.71
- CNTX $0.77
- 52 Week High
- LSF $10.90
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- LSF 46.79
- CNTX 39.82
- Support Level
- LSF $6.89
- CNTX $0.77
- Resistance Level
- LSF $7.72
- CNTX $0.87
- Average True Range (ATR)
- LSF 0.47
- CNTX 0.08
- MACD
- LSF -0.01
- CNTX 0.01
- Stochastic Oscillator
- LSF 32.97
- CNTX 20.75
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.